Oxytocin: a proven labour drug, and a nasal spray that hasn’t lived up to the hype

Oxytocin leads two very different lives. As an injection it is a standard drug in maternity care, licensed to start or strengthen labour and to prevent heavy bleeding after birth, and the evidence behind that use is solid [2,4]. As a nasal spray, it became famous as a “trust” or “bonding” hormone after a 2005 study, but careful replications haven’t reproduced that effect, and the largest autism trial, in 290 children, found no benefit over placebo [7,11].

What oxytocin is

Oxytocin is a nine-amino-acid hormone made in the hypothalamus and released from the back of the pituitary gland. Its sequence, Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly, was worked out by Vincent du Vigneaud’s laboratory in 1953 [1]. The two cysteines are linked into a small ring, and the molecule is closely related to vasopressin, the water-balancing hormone; the two differ at just two positions [2]. That kinship matters, because at high doses oxytocin can act a little like vasopressin, holding on to water [2].

Its best-understood jobs are in reproduction: it makes the womb contract during labour and triggers milk let-down during breastfeeding. The womb has oxytocin receptors whose numbers rise sharply during pregnancy, peaking in early labour at term [2].

Its reputation as a social hormone comes mainly from rodent studies, where manipulating the brain’s oxytocin system changed parental behaviour, social bonding and recognition of other animals [14]. Those effects were produced by acting directly on the brain, which is very different from spraying it up a person’s nose.

The licensed use: labour and bleeding after birth

In the US, synthetic oxytocin is sold as Pitocin, an injection for intravenous infusion or intramuscular use. It is licensed to induce labour when there’s a medical reason, to strengthen weak contractions, and after delivery to produce contractions and control postpartum bleeding [2]. The US label says specifically that it is not indicated for elective induction, meaning induction without a medical reason [2]. In the UK the equivalent product is Syntocinon, licensed for induction for medical reasons and other obstetric uses [3].

The evidence for preventing haemorrhage is strong by the standards of this site.

Against placebo, preventive oxytocin reduced the risk of losing more than 500 mL of blood (RR 0.53, 95% CI 0.38 to 0.74; six trials, 4,203 women) and the need for further uterus-contracting drugs (RR 0.56) [4]. Compared with ergot drugs, it caused much less nausea and vomiting [4].

It is also a powerful drug with real risks when misused. The US label lists maternal deaths from hypertensive episodes, brain haemorrhage and rupture of the womb in association with oxytocic drugs, and warns of water intoxication at high doses [2]. That’s why it’s given under monitoring on labour wards.

The nasal spray and “trust”

In 2005 a Zurich team published a study in Nature in which healthy volunteers who inhaled oxytocin before playing an investment game handed more money to a stranger, which the authors interpreted as increased trust [5]. The paper set off a decade of research linking oxytocin to trust through nasal-spray experiments, blood measurements and genetic studies [6].

The replications went badly. A 2015 review by Nave, Camerer and McCullough concluded that the headline trust finding “has not replicated well” and that blood oxytocin measurements used in many studies were unreliable [6]. In 2020, a group that included Ernst Fehr, one of the original 2005 authors, ran a pre-registered replication with enough participants to have more than 95% power and found no effect of oxytocin on trust in the condition closest to the original [7]. A 2026 Dutch replication in 211 people, pooled with the 2020 data for 532 people in total, again found no evidence that oxytocin increases trusting behaviour and concluded any effect is too small to matter for most lab studies [8].

Two 2016 analyses explain why so many early findings may have been false alarms. Walum and colleagues at Emory showed that most intranasal oxytocin studies were underpowered and concluded there is “a high probability” that most published findings don’t represent true effects [14]. Leng and Ludwig pointed out that very little of a nasal dose appears to reach the fluid around the brain, while blood levels rise far above normal, so effects could come from actions on the gut, heart or elsewhere [13].

What about oxytocin blood tests?

You’ll often see claims that hugging, eye contact or a good relationship “raises oxytocin”, usually based on blood or saliva measurements. Be wary. The 2015 trust review concluded the plasma oxytocin evidence was flawed by the way oxytocin is measured in body fluids [6], and Leng and Ludwig wrote that many published measurements used “discredited methodology” and that claims that blood levels reflect release in the brain are “questionable at best” [13]. Large genetic studies also failed to find consistent links between common variants in the oxytocin receptor gene and trust [6]. None of that means oxytocin plays no part in human social life. It means the popular shorthand has run far ahead of what’s been measured reliably.

Autism: from promise to a negative large trial

Autism was the clinical hope for nasal oxytocin. An early crossover study in 16 teenage boys found a single dose improved performance on the Reading the Mind in the Eyes test of emotion recognition [9]. But when the same Australian group gave 50 boys eight weeks of twice-daily spray, there was no benefit on the main or secondary outcomes [10]. One striking detail: parents who believed their child was on oxytocin reported more improvement than those who believed their child was on placebo, whatever the child had actually received [10].

The US trial led by Sikich and colleagues randomised 146 children to oxytocin and 144 to placebo and followed them for 24 weeks [11]. Both groups improved slightly and by almost exactly the same amount on the primary measure of social withdrawal [11]. The authors noted that oxytocin had already been given in clinical practice to many children with autism, which makes the negative result especially useful [11].

A 2022 Japanese trial tried a new spray designed to deliver more oxytocin, in 109 adult men with autism, testing four doses in a crossover design [12]. The main analysis wasn’t statistically significant; one dose looked better only in the per-protocol analysis, which excluded people who didn’t stick to treatment [12]. The authors described it as exploratory.

Safety and side effects reported

For the injection, the risks are well documented and mostly relate to overstimulating the womb, blood pressure spikes and water retention at high doses [2]. For the nasal spray, the trials reported it as well tolerated: side effects in the Sikich trial were similar in incidence and severity between oxytocin and placebo [11], and the 2015 Australian trial found no increase in side effects [10]. Those trials lasted weeks to months. Longer-term effects of daily use, especially in children, are unknown.

Legal and regulatory status

Oxytocin injection is a licensed prescription medicine in the US (Pitocin) [2] and the UK (Syntocinon) [3] for obstetric use. No nasal oxytocin product is approved in the UK or US for autism, social anxiety, relationships or any other psychiatric or social use; in research it is given under trial protocols. Products sold online as “oxytocin” nasal sprays or research peptides aren’t regulated as medicines.

What we still don’t know

• How much nasal oxytocin actually reaches the human brain, and whether any behavioural effect comes from the brain or the body.
• Whether any subgroup of people with autism benefits, since the large trials found no overall effect.
• Whether effects on social behaviour in the lab, if they exist, are large enough to matter in daily life.
• Long-term safety of repeated nasal use, especially in children.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.

Free live webinar · Thursday 1 October · 7pm UK time

Join the next webinar: Introduction to Peptides

with Mitch O’Callaghan, ISSCA Peptide Therapist · Founder, Proper Protocols

Save my free placeHPR×Proper Protocols